[1] Singh N, Baby D, Rajguru JP, et al. Inflammation and cancer[J]. Ann Afr Med, 2019, 18(3):121-126.
[2] Mukherjee PK, Sendid B, Hoarau G, et al. Mycobiota in gastrointestinal diseases[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(2):77-87.
[3] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis[J]. Nature, 2014, 513(7516):59-64.
[4] Mäkinen A, Nawaz A, Mäkitie A, et al. Role of non-albicans Candida and Candida albicans in oral squamous cell cancer patients[J]. J Oral Maxillofac Surg, 2018, 76(12):2564-2571.
[5] Sankari SL, Mahalakshmi K, Kumar VN. A comparative study of Candida species diversity among patients with oral squamous cell carcinoma and oral potentially malignant disorders[J]. BMC Res Notes, 2020, 13(1):488.
[6] Dwivedi PP, Mallya S, Dongari-Bagtzoglou A. A novel immunocompetent murine model for Candida albicans promoted oral epithelial dysplasia[J]. Med Mycol, 2009, 47(2):157-167.
[7] Alnuaimi AD, Wiesenfeld D, O'Brien-Simpson NM, et al. Oral Candida colonization in oral cancer patients and its relationship with traditional risk factors of oral cancer:a matched case-control study[J]. Oral Oncol,2015,51(2):139-145.
[8] Koo S, Kejariwal D, Al-Shehri T, et al. Oesophageal candidiasis and squamous cell cancer in patients with gain-of-function STAT1 gene mutation[J]. United European Gastroenterol J, 2017, 5(5):625-631.
[9] Delsing CE, Bleeker-Rovers CP, van de Veerdonk FL, et al. Association of esophageal candidiasis and squamous cell carcinoma[J]. Med Mycol Case Rep, 2012, 1(1):5-8.
[10] Chung LM, Liang JA, Lin CL, et al. Cancer risk in patients with candidiasis:a nationwide population-based cohort study[J]. Oncotarget, 2017, 8(38):63562-63573.
[11] Nørgaard M, Thomsen RW, Farkas DK, et al. Candida infection and cancer risk:a Danish nationwide cohort study[J]. Eur J Intern Med, 2013, 24(5):451-455.
[12] Richard ML, Sokol H. The gut mycobiota:insights into analysis, environmental interactions and role in gastrointestinal diseases[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6):331-345.
[13] Klimesova K, Jiraskova Zakostelska Z, Tlaskalova-Hogenova H. Oralbacterial and fungal microbiome impacts colorectal carcinogenesis[J]. Front Microbiol, 2018, 9:774.
[14] Luan C, Xie L, Yang X, et al. Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas[J]. Sci Rep, 2015, 5:7980.
[15] Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD[J]. Gut, 2017, 66(6):1039-1048.
[16] Wang T,Fan C,Yao A,et al. The adaptor protein CARD9 protects against colon cancer by restricting mycobiota-mediated expansion of myeloid-derived suppressor cells[J]. Immunity, 2018, 49(3):504-514.
[17] Huang J, Roosaar A, Axéll T, et al. A prospective cohort study on poor oral hygiene and pancreatic cancer risk[J]. Int J Cancer, 2016:138(2):340-347.
[18] Aykut B, Pushalkar S, Chen R, et al. The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL[J]. Nature, 2019, 574(7777):264-267.
[19] Harpf V, Rambach G, Würzner R, et al. Candida and complement:New aspects in an old battle[J]. Front Immunol, 2020, 11:1471.
[20] Ramirez-Garcia A, Gallot N, Abad A,et al. Molecular fractionation and characterization of a Candida albicans fraction that increases tumor cell adhesion to hepatic endothelium[J]. Appl Microbiol Biotechnol, 2011, 92(1):133-145.
[21] Ramirez-Garcia A, Arteta B, Abad A, et al. Candida albicans increases tumor cell adhesion to endothelial cells in vitro:intraspecific differences and importance of the mannose receptor[J]. PLoS One, 2013, 8(1):e53584.
[22] Ramirez-Garcia A, Rementeria A, Aguirre-Urizar JM, et al.Candida albicans and cancer:Can this yeast induce cancer development or progression[J]? Crit Rev Microbiol, 2016, 42(2):181-193.
[23] 王立东,宋昕,赵学科,等.食管癌环境和遗传危险因素交互作用的分子基础和精准预防[J]. 中国肿瘤临床, 2016, 43(12):515-520.
[24] Hooper SJ, Wilson MJ, Crean SJ. Exploring the link between microorganisms and oral cancer:a systematic review of the literature[J]. Head Neck, 2009, 31(9):1228-1239.
[25] Ho J, Camilli G, Griffiths JS,et al. Candida albicans and candidalysin in inflammatory disorders and cancer[J]. Immunology, 2021, 162(1):11-16.
[26] Moyes DL, Wilson D, Richardson JP, et al. Candidalysin is a fungal peptide toxin critical for mucosal infection[J]. Nature, 2016, 532(7597):64-68.
[27] Conti HR, Peterson AC, Brane L, et al. Oral-resident natural Th17 cells and γδ T cells control opportunistic Candida albicans infections[J]. J Exp Med, 2014, 211(10):2075-2084.
[28] Chang SH. T helper 17(Th17) cells and interleukin-17(IL-17) in cancer[J]. Arch Pharm Res, 2019, 42(7):549-559.
[29] Stary' L, Mezerová K, Vysloužil K, et al. Candida albicans culture from a rectal swab can be associated with newly diagnosed colorectal cancer[J]. Folia Microbiol (Praha), 2020, 65(6):989-994.
[30] Yang SF, Chen MK, Hsieh YS, et al. Prostaglandin E2/EP1 signaling pathway enhances intercellular adhesion molecule 1(ICAM-1) expression and cell motility in oral cancer cells[J]. J Biol Chem, 2010, 285(39):29808-29816.
[31] Jiang YX, Yang SW, Li PA, et al. The promotion of the transformation of quiescent gastric cancer stem cells by IL-17 and the underlying mechanisms[J]. Oncogene, 2017, 36(9):1256-1264.
[32] Rao M, Dodoo E, Zumla A, et al. Immunometabolism andpulmonary infections:implications for protective immune responses and host-directed therapies[J]. Front Microbiol, 2019, 10:962.
[33] Patel CH, Leone RD, Horton MR, et al. Targeting metabolism to regulate immune responses in autoimmunity and cancer[J].Nat Rev Drug Discov, 2019, 18(9):669-688. |
